Electroporation Instruments Market
Electroporation is a useful molecular biology technique that allows for non-chemical transformation of bacteria and yeasts as well as transfection of tissue culture cells (e.g. mammalian cells). Electroporation systems deliver short bursts of a high-intensity electric field to cells. The electrical field makes the cell membrane more permeable. As a result, chemicals such as drugs and genetic material can pass through the cell membrane, which would otherwise be impermeable. Due to its ease of use and efficacy, electroporation is a popular method for introducing foreign genes into target cells. In addition to direct gene introduction, electroporation allows for the direct transfer of plasmids between cells or species—for instance, from bacteria to yeast. Extensive research is ongoing on the use of electroporation to deliver medicines and vaccines directly to the cells of living organisms. Electroporation systems are commonly used for the treatment of cancer through vaccine delivery, gene delivery or drug delivery that is electrochemotherapy, for instance bleomycin Vaccine delivery can also be used for treatment of infectious disease such as Human immunodeficiency virus (HIV).
Market Dynamics
Key players operating in the global electroporation instruments market are focusing on growth strategies such as rebranding and agreements which is expected to drive the market growth during the forecast period. For instance, The Company is now operating as Eppendorf SE with immediate effect. Eppendorf AG was restructured into a European Company (Societas Europaea, SE) under the name Eppendorf SE, effective October 19, 2021. This change of legal form to an SE does not affect any existing business relationships with their partners; existing contractual relationships in particular continue unchanged. Moreover, On July 15, 2022, MaxCyte, Inc. had announced the Strategic Platform License (SPL) signed with LG Chem Ltd., a global diversified chemical company .Under the terms of the agreement, LG Chem will receive non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to platform license fees and program-related revenues.
Key features of the study
Market Segmentation
Table of Contents
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
